Cover Image

Oral yohimbine as a new probe drug to predict CYP2D6 activity: results of a fixed-sequence phase I trial

Yohimbine pharmacokinetics were determined after oral administration of a single oral dose of yohimbine 5 mg and a microdose of yohimbine 50 µg in relation to different cytochrome P450 (CYP) 2D6 genotypes. The CYP2D6 inhibitor paroxetine was used to investigate the influence on yohimbine pharmacokin...

Full description

Saved in:
Bibliographic Details
Main Authors: Vay, Manuela (Author) , Meyer, Marleen J. (Author) , Blank, Antje (Author) , Skopp, Gisela (Author) , Rose, Peter (Author) , Tzvetkov, Mladen Vassilev (Author) , Mikus, Gerd (Author)
Format: Article (Journal)
Language:English
Published: 15 February 2020
In: Clinical pharmacokinetics
Year: 2020, Volume: 59, Issue: 7, Pages: 927-939
ISSN:1179-1926
DOI:10.1007/s40262-020-00862-6
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s40262-020-00862-6
Get full text
Author Notes:Manuela Vay, Marleen Julia Meyer, Antje Blank, Gisela Skopp, Peter Rose, Mladen Vassilev Tzvetkov, Gerd Mikus
Description
Summary:Yohimbine pharmacokinetics were determined after oral administration of a single oral dose of yohimbine 5 mg and a microdose of yohimbine 50 µg in relation to different cytochrome P450 (CYP) 2D6 genotypes. The CYP2D6 inhibitor paroxetine was used to investigate the influence on yohimbine pharmacokinetics. Microdosed midazolam was applied to evaluate a possible impact of yohimbine on CYP3A activity and the possibility of combining microdosed yohimbine and midazolam to simultaneously determine CYP2D6 and CYP3A activity.
Item Description:Gesehen am 12.08.2021
Physical Description:Online Resource
ISSN:1179-1926
DOI:10.1007/s40262-020-00862-6

Similar Items